New Alzheimer's drug THN391 enters first patient trial
NCT ID NCT06814730
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests an experimental drug called THN391 in 15 people with early Alzheimer's disease who also have small vessel disease in the brain. Participants receive three monthly IV infusions of either THN391 or a placebo. The main goal is to check safety and how the drug behaves in the body, not yet whether it helps memory or thinking.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
THN391 (an experimental drug given by IV infusion)
What this could lead to
If this drug is safe and well-tolerated, it could pave the way for larger studies to see if THN391 can slow or treat Alzheimer's disease.
What could go wrong
This is a very early, small study (15 people) focused only on safety and drug levels—not on whether it works. Many drugs that look safe in Phase 1 fail later. There may be side effects or no benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE, EARLY ONSET are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amsterdam UMC
RECRUITINGAmsterdam, New Hampshire, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
CTC-Netherlands
RECRUITINGGroningen, 9713 EZ, Netherlands
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Scottish Brain Sciences
RECRUITINGEdinburgh, EH12 9DQ, United Kingdom
Contact Email: •••••@•••••
Contact
-
University College London Hospitals
RECRUITINGLondon, WC1N 3BG, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact